drugset / Trial / NCT05585580
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line immunotherapy.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2026-04-30
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Paclitaxel liposome | Unknown | 135 mg/m2 | — |
| Subject | Paclitaxel liposome | Unknown | 175 mg/m2 | — |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | — |